Background MYCN amplification (MYCN-A) is an established adverse prognostic factor in neuroblastoma. The extent to which the prognostic impact of MYCN-A depends on other factors has not been fully characterized. Patients and methods Using the International Neuroblastoma Risk Group database, we constructed Cox models of overall survival (OS) to obtain hazard ratios of the effect of MYCN-A within subgroups defined by other prognostic factors. Cox models assessed the degree to which the prognostic impact of MYCN-A was modulated by each other covariate. We used absolute hazard ratio (HR) differences to construct classification trees to identify subgroups with greatest differential prognostic effect of MYCN-A. Results In a cohort of 6223 patient...
BACKGROUND: The European multicenter study LNESG1 was designed to evaluate the safety and efficacy...
Although high-risk neuroblastoma (HR-NB) is clinically heterogeneous, it is treated in a similar fas...
Risk stratification is crucial to treatment decision-making in neuroblastoma. This study aimed to ex...
BACKGROUND:MYCN amplification (MYCN-A) is an established adverse prognostic factor in neuroblastoma....
BACKGROUND:MYCN amplification (MYCN-A) is an established adverse prognostic factor in neuroblastoma....
Background: To identify variables predicting outcome in neuroblastoma patients assigned to the high-...
BackgroundMYCN gene amplification (MNA) is a hallmark of aggressive neuroblastoma. This study was pe...
Background: To identify variables predicting outcome in neuroblastoma patients assigned to the high-...
BACKGROUND: Current risk stratification systems for neuroblastoma patients consider clinical, histop...
BACKGROUND: Current risk stratification systems for neuroblastoma patients consider clinical, histop...
Background In neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA)...
Background: MYCN status is reported to have a reproducible relationship to mitotic and karyorrhectic...
In 1983, the MYCN oncogene amplification was discovered in neuroblastoma cells and few years later i...
The MYC oncogenes are the most commonly amplified loci in medulloblastoma, and have previously been ...
This multicentric analysis of tumours obtained from 140 patients with neuroblastoma confirms that th...
BACKGROUND: The European multicenter study LNESG1 was designed to evaluate the safety and efficacy...
Although high-risk neuroblastoma (HR-NB) is clinically heterogeneous, it is treated in a similar fas...
Risk stratification is crucial to treatment decision-making in neuroblastoma. This study aimed to ex...
BACKGROUND:MYCN amplification (MYCN-A) is an established adverse prognostic factor in neuroblastoma....
BACKGROUND:MYCN amplification (MYCN-A) is an established adverse prognostic factor in neuroblastoma....
Background: To identify variables predicting outcome in neuroblastoma patients assigned to the high-...
BackgroundMYCN gene amplification (MNA) is a hallmark of aggressive neuroblastoma. This study was pe...
Background: To identify variables predicting outcome in neuroblastoma patients assigned to the high-...
BACKGROUND: Current risk stratification systems for neuroblastoma patients consider clinical, histop...
BACKGROUND: Current risk stratification systems for neuroblastoma patients consider clinical, histop...
Background In neuroblastoma (NB), the most powerful prognostic marker, the MYCN amplification (MNA)...
Background: MYCN status is reported to have a reproducible relationship to mitotic and karyorrhectic...
In 1983, the MYCN oncogene amplification was discovered in neuroblastoma cells and few years later i...
The MYC oncogenes are the most commonly amplified loci in medulloblastoma, and have previously been ...
This multicentric analysis of tumours obtained from 140 patients with neuroblastoma confirms that th...
BACKGROUND: The European multicenter study LNESG1 was designed to evaluate the safety and efficacy...
Although high-risk neuroblastoma (HR-NB) is clinically heterogeneous, it is treated in a similar fas...
Risk stratification is crucial to treatment decision-making in neuroblastoma. This study aimed to ex...